KRAS and neoplasm: Since all PDOs except HCT70-10T1 were derived from adenomatous lesions and did not show tumor-forming capability, these observations suggest that the constitutive activation of KRAS signaling is an early event in the adenoma-carcinoma sequence and is insufficient for the progression to carcinoma.